Search Medical Condition
Please enter condition
Please choose location from dropdown

New Hyde Park, New York Clinical Trials

A listing of New Hyde Park, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (915) clinical trials

Phase

0.0 miles

Learn More »

ADAPT - A Patient Registry of the Real-world Use of Orenitram

This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation

Phase N/A

0.0 miles

Learn More »

Adults with Diamond Blackfan Anemia and are currently receiving red blood cell transfusion therapy, are asked to participate in a research study being conducted by Cohen Children’s Medical Center of New York. Patient Inclusion Criteria: You may be eligible to participate in this study if you: Are 18 years old ...

Phase N/A

0.0 miles

Learn More »

Pharmacokinetics Efficacy and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients With Congenital Afibrinogenemia

This study is a phase I-II, multi-center, prospective, open-label, single-arm, clinical trial to evaluate PK, efficacy, and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in adult and pediatric subjects with congenital afibrinogenemia. Approximately 10 adult subjects (18 years) with congenital afibrinogenemia will be administered a single dose of FIB ...

Phase

0.0 miles

Learn More »

Serratus Plane Block for Postoperative Pain Control

This is a randomized, double-blinded, placebo-controlled trial of serratus plane blocks in subjects undergoing outpatient unilateral or bilateral breast surgery. Ninety subjects will be enrolled into the study at presurgical testing. Subjects will be stratified based on surgery type and randomized to receive a serratus plane block with either bupivicaine ...

Phase

0.0 miles

Learn More »

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with olaparib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the deleterious genetic alterations in the DNA damage ...

Phase

0.0 miles

Learn More »

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with JNJ-42756493 (erdafitinib) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4 pathway. SECONDARY OBJECTIVES: I. To estimate ...

Phase

0.0 miles

Learn More »

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with ensartinib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor ALK or ROS1 fusions or that harbor ALK missense mutations. SECONDARY OBJECTIVES: ...

Phase

0.0 miles

Learn More »

Blinatumomab and Combination Chemotherapy or Dasatinib Prednisone and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

PRIMARY OBJECTIVES: I. To evaluate the 3-year survival rate in elderly patients with newly diagnosed Philadelphia (Ph)-negative acute lymphoblastic leukemia (ALL) treated with blinatumomab followed by POMP (prednisone, vincristine sulfate, methotrexate, and mercaptopurine) maintenance. II. To evaluate in a preliminary manner (feasibility study) the safety of dasatinib-steroid based induction followed ...

Phase

0.0 miles

Learn More »

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...

Phase

0.0 miles

Learn More »